EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis

Parsa Radfar, Andrei I Gritsiuta, Margaux Marinelli, Joshua Yazditabar, Shawn P Nishi, Maurice Willis, Roman V Petrov

Clinical and Translational Oncology · 02.11.2026

DOI: 10.1007/s12094-026-04599-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 02.11.2026. Verfasst von Parsa Radfar und 6 weiteren Autor:innen. Beteiligte Einrichtung: John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, 301 University Blvd, TX, 77555. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pretreatment antibiotic exposure has been associated with inferior outcomes during immune checkpoint inhibitor (ICI) therapy, but whether this reflects an ICI specific effect or underlying clinical vulnerability remains uncertain.

Methods

Adults with non-small cell lung cancer (NSCLC) treated with ICIs from 2015 through 2024 were identified in the TriNetX Research Network. Recent antibiotic exposure was defined as systemic antibiotic use during days 30 to 1 before ICI initiation. Propensity score matching balanced clinical and treatment-related covariates. Primary outcomes were all cause mortality at 90 and 365 days. Sensitivity analyses included landmarking, remote exposure, infection stratification, and a non-ICI comparator.

Results

Among 68,723 patients, 19,080 had recent antibiotic exposure; 17,955 per group remained after matching. Mortality was higher with antibiotic exposure at 90 days (17.7% vs 13.7%; HR 1.34, 95% CI 1.27 to 1.41; P

Schlagwörter

Stichwörter der Autor:innen

AntibioticsImmune checkpoint inhibitorsImmunotherapyMicrobiomeNon-small cell lung cancer

Autor:innen und Institutionen

  • John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, 301 University Blvd, TX, 77555.
  • Division of Cardiovascular and Thoracic Surgery, University of Texas Medical Branch, Galveston, USA, TX. aigritsi@utmb.edu.
  • Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Medical Branch, Galveston, USA, TX.
  • Division of Medical Oncology and Hematology, University of Texas Medical Branch, Galveston, TX, USA.
  • Division of Cardiovascular and Thoracic Surgery, University of Texas Medical Branch, Galveston, USA, TX.

Zitieren

APA

Radfar, P., Gritsiuta, A. I., Marinelli, M., Yazditabar, J., Nishi, S. P., Willis, M., & Petrov, R. V. (2026). Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04599-9

Vancouver

Radfar P, Gritsiuta AI, Marinelli M, Yazditabar J, Nishi SP, Willis M, et al. Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04599-9

BibTeX
@article{Radfar2026,
  author = {Radfar, Parsa and Gritsiuta, Andrei I and Marinelli, Margaux and Yazditabar, Joshua and Nishi, Shawn P and Willis, Maurice and Petrov, Roman V},
  title = {Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04599-9}
}
Kostenlos starten →